Document:

Supply Agreement

 Exhibit 10.15 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 

Index of Contents 
  

							
			
	 1.
	  	DEFINITIONS	  	 	1	  
			
	 2.
	  	MANUFACTURE AND SALE	  	 	3	  
			
	 3.
	  	EXCLUSIVITY	  	 	3	  
			
	 4.
	  	RIGHT OF FIRST REFUSAL	  	 	4	  
			
	 5.
	  	FORECASTS, ORDERS AND DELIVERY	  	 	5	  
			
	 6.
	  	PRICES AND PAYMENT	  	 	6	  
			
	 7.
	  	REGULATORY RESPONSIBILITY	  	 	7	  
			
	 8.
	  	QUALITY CONTROL REQUIREMENTS	  	 	8	  
			
	 9.
	  	REJECTION	  	 	9	  
			
	 10.
	  	WARRANTY	  	 	10	  
			
	 11.
	  	INDEMNIFICATION	  	 	12	  
			
	 12.
	  	REPRESENTATIONS	  	 	12	  
			
	 13.
	  	TERM AND TERMINATION	  	 	13	  
			
	 14.
	  	MISCELLANEOUS	  	 	14	  
		
	 EXHIBIT A: DEVICE SPECIFICATION
	  	 	18	  
		
	 EXHIBIT B: SELLER CERTIFICAT OF ANALYSIS + SELLER STANDARD SPECIFICATION
	  	 	19	  
		
	 EXHIBIT C: PURCHASE PRICE
	  	 	20	  
		
	 EXHIBIT D: EXCLUSIVITY
	  	 	23	  
		
	 EXHIBIT E: STANDARD TERMS AND CONDITIONS
	  	 	25	  
		
	 EXHIBIT F: STANDAR PACKAGING AND PACKING SPECIFICATIONS
	  	 	27	  

 SUPPLY AGREEMENT 

This SUPPLY AGREEMENT (the “Agreement”), effective as of the seventh day of March, 2011 (the “Effective
Date”), is made and entered into by and between Insys Therapeutics, Inc., a Delaware corporation having its principal place of business at 10220 South 51st St., Suite 2, Phoenix, AZ 85044-5231 (hereinafter called
“PURCHASER”) and Aptargroup, Inc., a Delaware corporation having its principal place of business at 475 West Terra Cotta, Suite E, Crystal Lake, IL, 60014-9695 (hereinafter called “SELLER”). PURCHASER and SELLER
being hereinafter called individually the “Party” and collectively the “Parties”. 
 WHEREAS SELLER is engaged
in the development and manufacture of dispensing systems for medical use, with particular reference to nasal and oral devices; 
 WHEREAS
PURCHASER desires to purchase the Device (defined below) for Purchaser’s own use with Drug Product (defined below), subject to the terms and conditions herein; and 
 WHEREAS SELLER desires to sell the Device to PURCHASER subject to the terms and conditions herein. 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the Parties agree as follows: 

 

	1.	DEFINITIONS 

 As used herein, the
following terms and expressions shall have the meanings set forth below: 
  

	 	1.1	“Affiliate” means any person or entity that directly or indirectly through one or more intermediaries’ Controls, is Controlled by, or is under
common Control with a Party, where “Control” means the direct or indirect, legal or beneficial ownership of more than fifty percent (50%) of the outstanding voting rights in a company. 

 

	 	1.2	“cGMP” means the current good manufacturing practices stipulated or promulgated from time to time by the Regulatory Authorities that are applicable to
the manufacture of the Device. 

  

	 	1.3	“Cumulative Yearly Quantity” means the cumulative total Minimum Yearly Quantity amount of the Device PURCHASER must procure from the SELLER to maintain
pricing levels as defined in Exhibit C. 

  

	 	1.4	“Development Activities” means all research and development activities related to the development of a drug (including alternative delivery systems)
through preclinical and clinical stages. 

  

	 	1.5	“Device” means the device described in the Device Specifications. 

  
 1 

	 	1.6	“Device Equipment” means the moulds and assembly machines required at SELLER’s premises to manufacture the Device in commercial quantities.

  

	 	1.7	“Device Equipment Contribution” means the PURCHASER’s [...***...] reimbursement of research and development costs of SELLER related to, but
not limited to, the Device Equipment as described in Exhibit C. 

  

	 	1.8	“Design” means any combination of outer shape and color of the Device. 

 

	 	1.9	“Device Specifications” means the Device’s specifications as described in Exhibit A. 

 

	 	1.10	“Drug Product” means the sublingual formulation of Fentanyl owned by PURCHASER and currently known as “Fentanyl SL”.

  

	 	1.11	“Effective Date” means the day inserted on the introductory clause of this Agreement. 

 

	 	1.12	“FDA Approval” means the approval of the new drug application (NDA) for the Finished Product by the Food and Drug Administration in the United States
of America (FDA). 

  

	 	1.13	 “Fentanyl” means the compound with molecular formula C22H28
N2O and IUPAC name N-(1-2-phenlyethyl)-4-piperidinyl)-N-phenylpropanamide . 

  

	 	1.14	“Fentanyl Market” means the total unit sales of all non-extended release pharmaceutical products containing Fentanyl as an active pharmaceutical
ingredient. 

  

	 	1.15	“Finished Product” means the Drug Product in conjunction with the Device. 

 

	 	1.16	“Intellectual Property” means all present and future intellectual property rights and information, material and trade secrets that relate to the Device
or the Drug Product, as the case may be, whether or not patentable, including any know-how. 

  

	 	1.17	“Marketing Approval” means, with respect to any country, the approval of any marketing application for the Finished Product by the appropriate
Regulatory Authority in such country, including (a) FDA Approval, (b) approval of a marketing authorization application by the EU Medicines Agency and (c) approval of other product registration application with respect to any other
territory. 

  

	 	1.18	“Minimum Yearly Quantity” means the minimum amount of the Device PURCHASER must procure from the SELLER per year as defined in Exhibit C.

  

	 	1.19	“Purchase Price” shall have the meaning set forth in Exhibit C. 

 

	 	1.20	“Regulatory Authority” or “Regulatory Authorities” means the United States Food and Drug Administration and any divisions thereof, any
equivalent agency of any other country and any division thereof, and any other applicable regulatory body. 

  
 ***Confidential
Treatment Requested 
 2 

	 	1.21	“Success Fee” means the fee to be paid by PURCHASER to SELLER as specified in Exhibit D upon successful FDA Approval. 

 

	2.	MANUFACTURE AND SALE 

  

	 	2.1	Supply and Purchase Obligations. SELLER agrees to manufacture and sell to PURCHASER, and PURCHASER agrees to purchase from SELLER, such quantities of the Device
as PURCHASER may order from SELLER in accordance with the terms and conditions of this Agreement. 

  

	 	2.2	Device Equipment. Seller will utilize Device Equipment for the manufacture of the Device. Ownership of Device Equipment shall remain with SELLER. In case
PURCHASER wants to obtain ownership of Device Equipment, it shall purchase from SELLER Device Equipment at a price to be agreed between Parties and pay the applicable German VAT at the time of transfer of ownership. No such purchase shall occur
without SELLER’s prior written consent. In no case shall Device Equipment leave SELLER’s premises. 

  

	 	2.3	cGMP Compliance. SELLER shall assemble and package the Device in accordance with the Device Specifications and applicable cGMP as of the Effective Date.

  

	 	2.4	Intellectual Property. Any Intellectual Property owned or controlled as of the Effective Date by PURCHASER, SELLER, or their Affiliates shall remain the absolute
unencumbered property of SELLER and PURCHASER respectively. SELLER shall own all arising Intellectual Property rights related to the Device. SELLER reserves the right to prosecute, maintain and defend SELLER’s Intellectual Property, at
SELLER’s discretion and expense. SELLER’s IP is broadly drafted and includes trade secrets and patents related to the Device. SELLER may have strategic reasons to defend or not such IP and will need flexibility to exercise in its own
discretion, particularly any IP that has applications to other SELLER’s products. 

  

	3.	EXCLUSIVITY 

  

	 	3.1	SELLER is willing to supply the Device to PURCHASER on an exclusive basis per the conditions and limitations set forth in Exhibit D. For the avoidance of doubt,
such Exclusivity does not contain any license for patents or technologies. Neither Party grants any licenses to the other party. 

  

	 	3.2	The SELLER agrees to that the PURCHASER has Design exclusivity to the Device. 

 

	 	3.3	The exclusivity rights granted to PURCHASER hereunder shall be valid for the duration of the Exclusivity Term (as defined in Exhibit D); provided, that,
if the exclusivity provisions in this Agreement are challenged by a third party or any governmental authority, PURCHASER shall, at SELLER’s option, either (i) defend, indemnify and hold harmless the SELLER, its Affiliates and their
directors, officers, 

  
 3 

	 	
employees and agents from and against any losses suffered or resulting from such challenge, or (ii) convert the exclusive rights herein to non-exclusive rights. 

 

	4.	RIGHT OF FIRST REFUSAL 

  

	 	4.1	Grant of Right of First Refusal. PURCHASER hereby grants SELLER the exclusive option (but not the obligation) to supply to PURCHASER all of its requirements of a
Drug Delivery System (as defined below) for any Alternate Route of Administration (as defined below) in accordance with the terms of this Article 4. For the avoidance of doubt, PURCHASER may not purchase from a Third Party, or develop and
manufacture internally, a Drug Delivery System for any Alternate Route of Administration, unless (a) SELLER does not exercise its right of first refusal in accordance with Section 4.4 or (b) the feasibility study referred to in
Section 4.5 below is not successful unless (c) PURCHASER is engaged in active development of such Drug Delivery System prior to the Effective Date. 

 

	 	4.2	Alternate Route of Administration Drug Development. PURCHASER agrees to notify SELLER in accordance with Section 4.4 about all Development Activities of any
“Alternate Route of Administration” for a new drug that occur after the Effective Date. “Alternate Route of Administration” means any route of administration for a drug including, but not limited to the current sublingual
route of administration, intranasal, pulmonary, buccal, topical, ophthalmic, and otic drug delivery but excluding oral solid dosing. 

  

	 	4.3	Alternate Route of Administration Drug Delivery Systems. PURCHASER agrees to notify SELLER about all Development Activities that would utilize any “Drug
Delivery System” for any Alternate Route of Administration. “Drug Delivery Systems” used for Alternate Route of Administration includes but are not limited to all forms of spray devices, metered pumps, metered valves,
continuous valves, dry powder inhalers, unit and bi dose devices, and dispensing closures. 

  

	 	4.4	 Exercise of Right of First Refusal. PURCHASER shall deliver a written notice informing the SELLER of any Development Activities for a new drug
involving an Alternate Route of Administration within [...***...] of starting any such activities, which notice shall include information describing such Development Activities and specify whether any Drug Delivery System is preferred or is
then being researched or assessed. Within [...***...] following SELLER’s receipt of such notice, SELLER shall notify PURCHASER of its intention to exercise the right of first refusal set forth in Section 4.1. If SELLER decides to
exercise such right, then (a) PURCHASER shall provide to SELLER all information related to the applicable Development Activities relevant for the design or manufacture of the Drug Delivery System and (b) SELLER shall have [...***...]
from the date all necessary information and materials are provided by PURCHASER to present a Drug Delivery 

  
 ***Confidential
Treatment Requested 
 4 

	 	
System for such Alternate Route of Administration to the PURCHASER, but in no event later than [...***...] from the date of SELLER’s notice unless PURCHASER is responsible for any
delays. 

  

	 	4.5	Feasibility Studies. If SELLER provides to PURCHASER within the allotted time a Drug Delivery System for use with any such Alternate Route of Administration
Development Activities, PURCHASER shall perform a feasibility study with SELLER’s Drug Delivery System in accordance with the terms of a feasibility agreement to be negotiated by the Parties in good faith. If such feasibility study is
successful (as defined in the feasibility agreement), PURCHASER will be required to move forward with SELLER’s Drug Delivery System and the Parties shall then negotiate a supply agreement under terms similar to this Agreement. If the
feasibility study is unsuccessful, PURCHASER is free to seek alternate partners for such Drug Delivery System. 

  

	5.	FORECASTS, ORDERS AND DELIVERY 

  

	 	5.1	Estimates and Forecasts. Prior to FDA Approval and upon SELLER’s request, beginning on the first day of each calendar quarter, PURCHASER shall provide
SELLER a non-binding written rolling estimate of purchases of the Device for the [...***...] following the calendar quarter in which such estimate is submitted (the “Estimate”). The Estimate shall specify the desired delivery
dates for each month submitted. PURCHASER shall use its best efforts to assure that each Estimate is accurate, provided however, that the Parties agree that such Estimate shall not constitute an obligation of PURCHASER to purchase the estimated
quantities contained in the Estimate. 

 Following FDA Approval, on the first day of each calendar quarter,
PURCHASER shall provide SELLER a written rolling forecast of purchases of the Device for the [...***...] following the calendar quarter in which such forecast is submitted (the “Forecast”). The Forecast shall specify the
desired delivery dates for each month submitted. PURCHASER shall use its best efforts to assure that each Forecast is accurate, provided however, that the Parties agree that such Forecast (other than the quantities set forth in the Purchase Order)
shall not constitute an obligation of PURCHASER to purchase the estimated quantities contained in the Forecast and that SELLER may charge PURCHASER for otherwise un-reimbursed charges incurred due to reasonable commitments made by SELLER to
suppliers based on such Forecast. PURCHASER agrees that the first [...***...] of each Forecast shall be a firm purchase order of the Device by PURCHASER for which SELLER is authorized to commence production, and which PURCHASER shall purchase
(the “Purchase Order”). 
  

	 	5.2	 Delivery. SELLER shall manufacture, package and deliver ordered quantities of the Device as long as such orders are within the scope of
confirmed Purchase Orders. SELLER shall promptly notify PURCHASER if it will be unable to deliver any part of an order exceeding the quantities set forth on the confirmation of the Purchase Order. SELLER shall not be obligated to supply in any month
any quantity of the 

  
 ***Confidential
Treatment Requested 
 5 

	 	
Device exceeding [...***...] of the Purchase Order, and PURCHASER shall purchase at least [...***...] of the quantities set forth in the Purchase Order. SELLER will use its reasonable
commercial efforts to deliver the Device within the time schedule set forth in the confirmation of the Purchase Order. 

  

	 	5.3	Terms of Delivery. Unless otherwise specified in the Purchase Order, SELLER of the Device to PURCHASER shall be via truck, and shall be delivered EXW Congers, NY
manufacturing site (INCOTERMS 2010) to the place of destination in the United States of America named in the Purchase Order. In the event PURCHASER requests SELLER to transport the Device to PURCHASER via air, PURCHASER shall bear all additional
costs of such air transportation. SELLER shall arrange for transportation of the Device by insured common carrier, or SELLER’s truck to PURCHASER’s specified plant or other designated destination in the United States of America. In the
event PURCHASER requires delivery to destination outside the United States of America, new delivery terms shall be negotiated. The Purchase Price for the Device is based on EXW Congers, NY manufacturing site (INCOTERMS 2010). If the Device is
manufactured outside the United States, SELLER and PURCHASER shall negotiate in good faith to agree on appropriate terms. 

  

	 	5.4	Shipment. SELLER shall ship the Device in multiples of full production lots, as defined in Exhibit C. SELLER shall deliver with each lot a Certificate of
Analysis substantially in the form attached hereto as Exhibit B. 

  

	6.	PRICES AND PAYMENT 

  

	 	6.1	Purchase Price. The Purchase Price for the Device is set forth in Exhibit C. 

 

	 	6.2	Payment for the Device. Payment related to the Device shall be made in full within [...***...] of the date of SELLER’s invoice. SELLER shall date and
send invoices for the Device upon shipment of the Device. 

  

	 	6.3	Taxes. The Purchase Price for the Device does not include any property, license, privilege, sales, service, use, excise, value added, gross receipts, or other
like taxes. PURCHASER agrees to pay or reimburse SELLER for any such taxes that SELLER is required to pay or collect or that are required to be withheld. 

  

	 	6.4	Payment of Success Fee. PURCHASER shall pay the Success Fee within [...***...] of the date of the SELLER’s invoice. SELLER shall date and send
invoices for the Success Fee upon the terms defined in Exhibit D. 

  

	 	6.5	Device Equipment Contribution. PURCHASER shall pay the Device Equipment Contribution within [...***...] of the date of the SELLER’s invoice. SELLER
shall date and send invoices upon the milestones defined in Exhibit C. 

  

	 	6.6	Currency. All payments hereunder shall be made in United States Dollars (USD). 

  
 ***Confidential
Treatment Requested 
 6 

	 	6.8	Interest. If PURCHASER fails to pay the full invoiced amount for the Device, or any part thereof, within [...***...] after the due date, SELLER shall be
entitled (without prejudice to any other right or remedy it may have whether under the terms of this Agreement or otherwise) to charge, in addition to any monies due hereunder, interest on the outstanding amount at the rate of [...***...] or
the highest applicable rate allowed by law, whichever is less, calculated on a daily basis from such date until the date actual payment is made. 

  

	 	6.8	Price Revision Due to Changes in Device Specifications. 

  

	 	6.8.1	By PURCHASER. 

 PURCHASER may
request a change, in writing, to the Device Specifications, the manufacturing procedures or control procedures. SELLER will use commercially reasonable efforts to implement the change subject to pricing adjustments, which will be negotiated in good
faith by SELLER and PURCHASER. 
  

	 	6.8.2	By SELLER. 

 SELLER will notify
PURCHASER in writing prior to implementing any change affecting the chemical, biological or physical aspects of the Device. SELLER will not make any changes to the Device Specifications without PURCHASER’s prior written consent shall not be
unreasonably withheld or delayed. SELLER will implement the change subject to pricing adjustments, which will be negotiated in good faith by SELLER and PURCHASER. 
  

	 	6.8.3	By Regulatory Authorities. 

 In
the event of changes required by cGMP’s or other applicable laws or regulations, or in the requirements for the Device, whether written or un-written, by the Regulatory Authorities, SELLER shall have the right to adjust the Purchase Price, such
adjustment being negotiated in good faith by SELLER and PURCHASER. 
  

	7.	REGULATORY RESPONSIBILITY 

  

	 	7.1	Regulatory Responsibility. SELLER shall be responsible, at its sole expense, for complying with applicable regulatory requirements relating to the manufacture of
the Device as applicable in SELLER’ s facilities where the Device is manufactured and, shall use commercially reasonable efforts to perform all of its responsibilities and obligations, including applicable design, development, manufacture,
testing, quality control and documentation activities relating to the Device under or contemplated by this Agreement substantially in accordance with all relevant quality standards that must be met to secure regulatory approval worldwide.

 PURCHASER shall be responsible, at its sole expense, for complying with all other applicable regulatory
requirements relating to the use and sale or resale of the Finished Product. 

  
 ***Confidential
Treatment Requested 
 7 

	 	7.2	Import and Export Laws. PURCHASER shall comply, at its sole expense, with all export and import regulations and laws necessary to export and import components of
the Device to and from PURCHASER’s premises, including without limitation, procuring and maintaining all import and export licenses necessary to ship from the point of manufacture to PURCHASER’ s premises in accordance herewith and the
payment of all duties, tariffs, surcharges and other customs and other governmental fees levied in connection with the exportation and importation of components of the Device from SELLER to PURCHASER’s premises, or such other location as
designated by PURCHASER. 

  

	8.	QUALITY CONTROL REQUIREMENTS 

  

	 	8.1	Quality 

  

	 	8.1.1	The Parties shall agree upon reasonable release tests to be performed by SELLER prior to shipment of the Device in accordance with applicable regulatory requirements
and subject to pricing conditions. Results of such testing will be supplied in the Certificate of Analysis with each shipment as seen in Exhibit B. 

  

	 	8.1.2	PURCHASER shall send prior written notice of any change requested to be made to Drug Product being delivered by the Device that PURCHASER suspects may affect the Device
Specifications. 

  

	 	8.1.3	Notwithstanding any provision to the contrary in this Agreement, SELLER shall not assign or otherwise delegate any of its obligations to ensure the Device’s
quality or compliance with Device Specifications to any third party other than an Affiliate without consent from the PURCHASER. 

  

	 	8.2	PURCHASER’s Inspections. 

  

	 	8.2.1	The Device shall be subjected to a quality control inspection by PURCHASER in accordance with the Device Specifications set forth in Exhibit A, within
[...***...] as from delivery of the Device to the location designated by PURCHASER in the applicable Purchase Order. 

  

	 	8.2.2	Upon reasonable prior notice, SELLER shall permit PURCHASER to review SELLER’ s quality control procedures and records related to the Device for the purpose of
assuring satisfactory compliance with the Device Specifications and compliance with the provisions of the Quality Agreement. That review shall be conducted in a reasonable manner, during SELLER’s business hours, in the presence of a SELLER
representative and at PURCHASER’s own expense. 

  

	 	8.2.3	 Upon reasonable prior notice, SELLER may permit PURCHASER’s quality assurance personnel to visit SELLER’s production facility, to the extent
that such visit is reasonably required to assure compliance with regulatory requirements or to the extent a review of records alone is not adequate to 

  
 ***Confidential
Treatment Requested 
 8 

	 	
assure satisfaction with such quality control requirements. Such visit shall be conducted in a reasonable manner, during SELLER’s business hours, in the presence of a SELLER representative,
at PURCHASER’s own expense and shall be limited to the equipment, records or production actually used in the manufacture of the Device. 

  

	 	8.2.4	SELLER shall (i) participate and cooperate with PURCHASER’s personnel who may visit SELLER’s production facility as provided in this Section 8,
(ii) take corrective action in a timely manner as may be reasonably required by PURCHASER to comply with the provisions of this Agreement and with cGMP requirements when applicable, subject to pricing conditions in Sections 4 and Exhibit
C, and (iii) when requested by PURCHASER, describe in writing, any appropriate corrective action planned or taken. 

  

	 	8.3	Regulatory Inspections. 

  

	 	8.3.1	In the event that any of SELLER’s products, facilities and/or processes that are used for the manufacture of the Device are the subject of an inspection related to
PURCHASER by any Regulatory Authority or any other duly authorized agency of any national, state, or local government, SELLER shall promptly notify PURCHASER of such inspection and shall supply PURCHASER with copies of any correspondence or portions
of correspondence that relate to the Device, as well as SELLER’ s proposed response, if any. 

  

	 	8.3.2	In the event that any of PURCHASER’s facilities that are used for the storage of the Device or the manufacturing of the Finished Product are the subject of an
inspection by any Regulatory Authority or any other duly authorized agency of any national, state, or local government, PURCHASER shall promptly notify SELLER of such inspection and shall supply SELLER with copies of any correspondence or portions
of correspondence that relate to the Device, as well as PURCHASER’s proposed response, if any. 

  

	 	8.3.3	In the event that either Party receives any written communications from any Regulatory Authority in connection with the manufacture, use, or sale of the Device for
PURCHASER, it shall provide the other Party with a copy of each such communication and the proposed response, if any. 

  

	 	8.3.4	Records. SELLER shall retain samples of the Device, batch and other manufacturing and analytical records, records of shipments of the Device and validation data
relating to the Device for a minimum of [...***...] and shall make such data available to PURCHASER and Regulatory Authorities upon PURCHASER’s reasonable request or if required by law. 

 

	9.	REJECTION 

  

	 	9.1	 General. In the event that any portion of the Device delivered to PURCHASER by SELLER shall fail to conform with the Device Specifications,
PURCHASER may 

  
 ***Confidential
Treatment Requested 
 9 

	 	
reject that portion by giving written notice within [...***...] following receipt of Products and sending, at SELLER’s expense, the defective samples to SELLER after SELLER’s
acceptance of rejection. Failure to report claim within that period, PURCHASER shall be considered as having accepted delivery and SELLER shall not be held liable with respect to the defective Device. 

 

	 	9.2	Unattributed Defects. In case the Device does not comply with the Device Specifications due to hidden or latent defects that were not noticeable at the time of
inspection by PURCHASER pursuant to Section 8.2, PURCHASER shall immediately inform SELLER of its claims in this respect, at the latest within the later period of [...***...] following the discovery of the defect or any third party or
regulatory claim or liability arising from the defect. Failing any claims within [...***...] in this respect, it shall not be possible to engage SELLER’s liability. Notwithstanding the foregoing, SELLER shall not be liable for any defect
appearing more than [...***...] after the Device (stored and handled in accordance with commercially reasonable standards) is received at PURCHASER’s premises. 

 

	 	9.3	Claims. Any and all claims shall be substantiated and explained in reasonable detail as to the nature of the defects or failure of the Device to comply with the
Device Specifications. PURCHASER shall reasonably provide SELLER with any and all substantiation regarding the reality of the anomalies recorded, notably with defective samples and shall ensure that SELLER has reasonable means of confirming the
existence of such anomalies. 

  

	 	9.4	Rejected Device. If PURCHASER rejects the Device in accordance with this Section 9, and after SELLER’s formal acceptance of such rejection, then, at
SELLER’s expense and discretion, PURCHASER shall return to SELLER any such shipment, or any part thereof, that does not comply with the Device Specifications, and receive in exchange therefore at the option of PURCHASER or SELLER, either
(i) a complete refund of the Purchase Price, taxes paid and not recoverable, and shipping costs associated with the Device in form of a credit note, or (ii) fully compliant replacement Device. If the Parties so agree, PURCHASER shall
destroy any non-conforming Device, at SELLER’s expense and in accordance with all applicable legal requirements. While SELLER is investigating the rejection, payments of purchased goods subject to such rejection shall be put on hold until claim
response is given. 

  

	 	9.5	Disputes. If SELLER disputes PURCHASER’s rejection, the Parties shall submit samples of the rejected Device to a mutually acceptable independent laboratory
for analysis, whose decision in the matter shall be final and binding. The costs of such analysis shall be borne by SELLER unless such analysis shows that the Device conforms to the Device Specifications, in which case PURCHASER shall bear the cost
of such analysis. 

  

	10.	WARRANTY 

  

	 	10.1	SELLER’s Warranty. 

  
 ***Confidential
Treatment Requested 
 10 

	 	10.1.1	SELLER warrants to PURCHASER that the Device, at the time of delivery to PURCHASER as provided in Section 5.2, will conform in all respects to the Device
Specifications. 

  

	 	10.1.2	SELLER does not warrant that the Device may be suitable for the manufacture of any intermediate or finished product (including the Finished Product).

  

	 	10.1.3	It is the exclusive responsibility of PURCHASER to ensure that (i) the Device shipped from SELLER according to the Device Specifications is adapted to the use
which it is intended for, (ii) that the Device Specifications are adapted to the storage of the Device, (iii) that the Device is compatible with the Drug Product, and (iv) that the Drug Product and the Finished Product (other than the
Device) comply with all applicable laws. 

  

	 	10.1.4	SELLER may, but is not required to, perform tests for compatibility between the Device and the Drug Product. SELLER MAKES NO REPRESENTATION OR WARRANTY THAT ANY TESTS
PERFORMED BY OR ON BEHALF OF SELLER ARE ADEQUATE OR SUFFICIENT FOR PURCHASER’S PURPOSES. PURCHASER AGREES NOT TO HOLD SELLER RESPONSIBLE FOR THE ADEQUACY OR SUFFICIENCY OF SUCH TESTS, OR THE RESULTS DERIVED FROM SUCH TESTS.

  

	 	10.2	Exclusions. The warranty provided under Section 10.1(a) shall not apply to any Device that (i) has been tampered with or otherwise altered by
PURCHASER, its Affiliates or their customers, distributors agents; (ii) has been subjected to misuse, negligence, malice or accident by PURCHASER, its Affiliates or their customers, distributors agents; or (iii) has been stored, handled or
used by PURCHASER, its Affiliates or their customers, distributors agents in a manner contrary to the Device Specifications and the Device Specifications or SELLER’s written instructions which can, among others, define maximum periods for the
use of the Device. 

  

	 	10.3	Limitations on Warranty. THE FOREGOING WARRANTIES ARE EXCLUSIVE AND IN LIEU OF ALL OTHER WARRANTIES OF QUALITY AND PERFORMANCE, WRITTEN, ORAL OR IMPLIED, AND ALL
OTHER WARRANTIES, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT, ARE HEREBY DISCLAIMED BY SELLER. 

 

	 	10.4	LIMITATION OF LIABILITY 

  

	 	10.4.1	 No Consequential Damages. IN NO EVENT SHALL SELLER BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, whether in warranty,
contract, negligence, tort, strict liability, or otherwise including, but not limited to, loss of profits or revenue, delays, or 

  
 11 

	 	
claims of customers of PURCHASER or its Affiliates or other third parties for such or other damages. This limitation of liability shall not apply to claims of liability for death or personal
injury caused by SELLER’s gross negligence, willful act, or omission. 

  

	 	10.4.2	Limitation of Liability. Each Party’s cumulative liability to the other Party for all claims relating to the Device and this Agreement, including any cause
of action based on any theory of contract, tort, or strict liability, shall not exceed One Million US Dollars ($1,000,000). This limitation of liability shall not apply to claims of liability for death or personal injury caused by either
Party’s gross negligence, willful act, or omission. In this respect, PURCHASER expressly undertakes to inform all of its customers, Affiliates or other third parties of the conditions and maximum periods defined for the use of the Device, by
any appropriate means making it possible to inform the said customers, Affiliates or other third parties, prior to use of the Device. 

  

	11.	INDEMNIFICATION 

  

	 	11.1	SELLER. Subject to the liability limitations set forth in clause 10.4, SELLER shall defend, indemnify and hold PURCHASER and its Affiliates, and their
shareholders, directors, officers, employees and agents harmless from and against any and all liability, loss, damage, recalls, causes of action, suits, claims, demands, settlements, costs and expenses or judgments arising from injury or death to
persons or damage to property, of any nature whatsoever, resulting from the failure of the Device to conform to the warranty set forth under Section 10.1, provided that PURCHASER shall have given prompt notice in writing to SELLER of any such
claim. 

  

	 	11.2	PURCHASER. PURCHASER shall defend, indemnify and hold SELLER and its Affiliates, their shareholders, directors, officers, employees and agents harmless from and
against any and all liability, loss, damage, expense, causes of action, suits, claims, demands, settlements, costs and expenses or judgments of any nature whatsoever, resulting from the Finished Product or its marketing, sale, clinical testing,
clinical use or other use or misuse, including any defect, failure to warn or other Device liability claims, except to the extent SELLER is required to indemnify PURCHASER under Section 10.1 of this Agreement, provided that SELLER shall have
given prompt notice in writing to PURCHASER of any such claim. 

  

	 	11.3	Insurance. Each of SELLER and PURCHASER will use its best efforts, by itself or through its Affiliates’ group insurance policies and at its sole cost and
expense, to procure and maintain adequate General & Products Liability Insurance. In addition, SELLER will use its best efforts, by itself or through its Affiliates’ group insurance policies and at its sole cost and expense, to procure
and maintain adequate Property All Risks Insurance in order to cover the value of the Device Equipment and any components thereof in SELLER’s possession or for which SELLER bears the risk of loss. 

 

	12.	REPRESENTATIONS 

  
 12 

	 	12.1	Each Party hereby represents and warrants that it has the full power and authority to enter into and perform this Agreement, and each Party knows of no contract,
agreement, promise, undertaking or other fact or circumstance that would prevent the full execution and performance of this Agreement. 

  

	13.	TERM AND TERMINATION 

  

	 	13.1	Term. This Agreement shall, unless otherwise terminated, remain in full force and effect for a period of five (5) years from the Effective Date (the
“Initial Term”), at which time, the Parties shall discuss in good faith negotiations an extension of this Agreement. 

  

	 	13.2	Early Termination. Without prejudice to any other rights it may have hereunder or at law or in equity, either Party may terminate this Agreement:

  

	 	13.2.1	immediately if the other Party makes an assignment for the benefit of its creditors or a receiver or custodian is appointed for it or its business is placed under
attachment, garnishment or other process involving a significant portion of its business; 

  

	 	13.2.2	after [...***...] written notice from the terminating Party specifying an alleged material breach (including payment breach) and stating its intent to so
terminate, if the other Party fails to commence and diligently pursue to remedy any such material breach of this Agreement; 

  

	 	13.2.3	immediately if the other Party becomes insolvent, an order for relief is entered against the other Party under any bankruptcy or insolvency laws or laws of similar
import; or 

  

	 	13.2.4	upon [...***...] written notice from the terminating Party if the Device does not receive FDA Approval by January 1, 2013. 

 

	 	13.3	Effect of Termination. Neither termination nor non-renewal of this Agreement shall release either Party from fulfilling any obligations it may have incurred
prior to any such termination, nor prejudice any other rights or remedies that either Party may have at law or in equity. 

 In case of early termination by PURCHASER not due to a breach by SELLER, PURCHASER will compensate SELLER for any costs directly related to the value of the goods or components already incurred by SELLER
on the basis of the Purchase Orders received from PURCHASER according to Section 5.1 above. PURCHASER will also compensate SELLER for any costs associated with stock at SELLER’s or at SELLER’s sub suppliers, including, but not limited
to, rubber stoppers, glass vials, and steel needles; provided SELLER and SELLER’s sub suppliers shall be obligated to take all commercially reasonable measures to mitigate the damages resulting from such remaining inventory. 

  
 ***Confidential
Treatment Requested 
 13 

	 	13.4	Surviving Clauses. Notwithstanding any such termination, any provision set forth in this Agreement remaining to be performed in whole or in part, capable of
taking effect following termination, or which by its nature is contemplated to survive the termination of this Agreement shall survive and continue in full force and effect despite termination. 

 

	14.	MISCELLANEOUS 

  

	 	14.1	Notices. All notices, requests, demands, waivers, consents, approvals or other communications to any Party hereunder shall be in writing and shall be deemed to
have been duly given if delivered personally to such Party or sent to such Party by facsimile transmission, overnight courier or by registered or certified mail, postage prepaid, to the addresses set forth below (or to such other address as the
addressee may have specified in notice duly given to the sender as provided herein): 

 If to SELLER:

 AptarGroup, Inc. 
 475 West Terra Cotta, Suite E 
 Crystal Lake, IL 60014-9695 USA 

Attn: Chief Operating Officer 
 Phone No.: (815) 477 -0424 
 Fax No.: (815) 477-0481 

    With cc to: 
 Aptar Congers, a division of AptarGroup, Inc. 
 250 North Route 303 

Congers, NJ 10920-1408 USA 
 Attn: President, Aptar Pharma North America 
 Phone No.: (845) 639-3700

 Fax No: (845) 639-3900 
 If to PURCHASER: 
 Name: INSYS 

10220 South 51st Street, Suite 2 
 Pheonix, AZ 85044 USA 
 Attn: President 

Phone No.: (602) 910 2617 x9021 
 Fax No.: (602) 910-2627 
 Such notice, request, demand, waiver, consent,
approval or other communications will be deemed to have been given as of the date so delivered, sent by facsimile transmission with receipt confirmed, or [...***...] after so mailed. 

 

	 	14.2	Choice of Law. This Agreement, along with the Schedules and Exhibits attached, incorporated and referenced herein and all Purchase Orders issued hereunder shall
be governed and interpreted, and all rights and obligations of the Parties shall be determined, in accordance to the laws of the State of New York. 

  
 ***Confidential
Treatment Requested 
 14 

	 	14.3	Force Majeure. Neither Party shall be responsible or liable in any way for failure or delay in carrying out the terms of this Agreement resulting from any cause
or circumstance beyond that Party’s reasonable control, including, but not limited to, fire, flood, other natural disasters, war, labor difficulties, interruption of transit, accident, explosion, civil commotion, and acts of any governmental
authority; nor shall SELLER be responsible or liable in any way for failure or delay in carrying out the terms of this Agreement if due to any shortage or inability to obtain any raw materials (including energy), equipment or transportation;
provided, in each case, that the affected Party shall give prompt notice thereof to the other Party. No such failure or delay shall terminate this Agreement, and each Party shall complete its obligations hereunder as promptly as reasonably
practicable following cessation of the cause or circumstances of such failure or delay; provided, that if any of the above conditions continues to exist for more than [...***...] after the date of any notice given with regard thereto, either
Party may terminate this Agreement forthwith upon notice to the other. 

  

	 	14.4	Severability. In the event that any provision of this Agreement shall be found in any jurisdiction to be in violation of public policy or illegal or
unenforceable at law or in equity, such finding shall in no event invalidate any other provision of this Agreement in that jurisdiction, and this Agreement shall be deemed amended to the minimum extent required to comply with the law of such
jurisdiction, such provision being adjusted rather than voided if possible. 

  

	 	14.5	Entire Agreement. This Agreement, including any Schedules and Exhibits attached, incorporated or referenced herein, the Quality Agreement, and the
confidentiality agreement referenced in Section 14.9 set forth the entire agreement reached between the Parties with respect to the transactions contemplated hereby. This Agreement (including all Schedules and Exhibits) may not be amended or
modified except by written instrument duly executed by the Parties hereto stating that it is an amendment to this Agreement. 

 With the reservation of the specific provisions of this Agreement and of the Quality Agreement, SELLER’s general conditions of sales, attached as Exhibit E, shall apply to all sales closed in the
framework of this Agreement, to the exclusion of any and all general conditions of purchase which may be communicated by PURCHASER. 
 The terms of this Agreement shall take precedence over the Qualtiy Agreement, the confidentiality agreement referenced in Section 14.9 or the standard terms and conditions set forth in Exhibit E if
there is any conflict between them. 
  

	 	14.6	No Waiver. The failure of either Party hereto to enforce at any time, or for any period of time, any provision of this Agreement shall not be construed as a
waiver of such provision or of the right of such Party thereafter to enforce each and every provision. Any waiver by a Party of any of its rights under this Agreement in one or more instances shall be in a writing signed by such Party and shall not
be construed as constituting a continuing waiver or as a waiver in other instances. 

  
 ***Confidential
Treatment Requested 
 15 

	 	14.7	Assignment, Binding Effect. Neither Party shall assign this Agreement nor any of its respective rights or obligations hereunder without the prior written consent
of the other Party, which consent will not be unreasonably withheld, except to any Affiliate of the assigning Party or by operation of law or as otherwise permitted hereunder. Any such attempted assignment without such consent shall be void. This
Agreement and the rights herein granted shall be binding upon and shall inure to the benefit of PURCHASER and SELLER and their respective successors and permitted assigns. 

 

	 	14.8	Arbitration. Any dispute, controversy or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity hereof, that the
Parties are unable to resolve between themselves, shall be settled by arbitration in accordance with the Rules of Arbitration of the International Chamber of Commerce, and judgment upon the award rendered by the arbitrator(s) may be entered in any
court having jurisdiction thereof. Such proceedings shall take place in New York, USA, and shall be conducted in English. The decision of the arbitration proceeding shall be final and binding upon the Parties. This clause shall not be construed to
limit the right of either Party to apply to any court of competent jurisdiction for injunctive relief for unauthorized use of confidential information. 

  

	 	14.9	Confidentiality. A separate agreement signed April 16, 2010 relating to confidentiality has been entered into by the Parties and that agreement constitutes
the entire agreement and understanding of the Parties relating to the subject matter of confidentiality and supersedes any previous agreement or understanding between the Parties in relation to such subject matter. 

[Signature page follows]. 

  
 16 

 IN WITNESS WHEREOF, this Agreement has been duly executed and delivered as of the day and year first above
written. 
  

					
	/s/ Stephen J. Hagge	 		 	/s/ Michael Babich
	 APTARGROUP, INC.
 Name: Stephen
J. Hagge
 Title: Exec. V.P. & Chief Operating Officer
 Date: May 26, 2011
	 		 	 INSYS THERAPEUTICS, INC.

Name: Michael Babich
 Title: President and
CEO
 Date: 5/31/11

 [Signature page of Supply Agreement between AptarGroup, Inc. and Insys Therapeutics, Inc.]

  
 17 

 EXHIBIT A: DEVICE SPECIFICATION 

[...***...] 

  
 ***Confidential
Treatment Requested 
 18 

 EXHIBIT B: SELLER CERTIFICAT OF ANALYSIS + SELLER STANDARD 

SPECIFICATION 
 [...***...] 

  
 ***Confidential
Treatment Requested 
 19 

 EXHIBIT C: PURCHASE PRICE 
 [The purchase price for the Device (“Purchase Price”) is based on the procured annual quantities of the Device in accordance with Table C1 below: 

Table C.1 Device Purchasing Price Levels 
  

					
	 Price Level
	  	 Quantities (pieces)
	  	 Price ([...***...])

	 1
	  	[...***...]	  	$[...***...]
	 2
	  	[...***...]	  	$[...***...]
	 3
	  	[...***...]	  	$[...***...]
	 4
	  	[...***...]	  	$[...***...]
	 5
	  	[...***...]	  	$[...***...]

 Notwithstanding the above, SELLER grants PURCHASER a Purchase Price equal to Price Level [...***...] subject to
PURCHASER’s procurement of the yearly quantity of units of the Device from the SELLER as described below in Table C.2. Year 1 is defined as the time period leading up to FDA Approval and the first year from the date of FDA Approval of the
Finished Product. For this time period a price of $[...***...] will be offered as long as Year 1 Minimum Yearly Quantity is met. Year 2 is defined as the second year from the date following FDA Approval. For this time period a price of
$[...***...] will be offered as long as Year 2 Minimum Yearly Quantity is met. Year 3 is defined as the third year from the date following FDA Approval of the Finished Product. For this time period a price of $[...***...] will be offered
as long as Year 3 Minimum Yearly Quantity is met. Year 4 is defined as the fourth year from the date following FDA Approval of the Finished Product. For this time period a price of $[...***...] will be offered as long as Year 4 Minimum Yearly
Quantity is met. 
 Table C.2 Minimum Yearly Quantities 
  

							
	 Year
	  	 Minimum Yearly
Quantity
	  	 Cumulative Yearly
Quantity
	  	 Price ([...***...])

	 1
	  	[...***...]	  	[...***...]	  	$[...***...]
	 2
	  	[...***...]	  	[...***...]	  	$[...***...]
	 3
	  	[...***...]	  	[...***...]	  	$[...***...]
	 4
	  	[...***...]	  	[...***...]	  	$[...***...]

 In case PURCHASER has not met the Minimum Yearly Quantities set forth in Table C.2 for any reason other than for
SELLER’s fault, pricing for the quantities purchased will be adjusted to the appropriate pricing level as outlined in Table C.1 above and a supplemental invoice will be issued for the difference retroactively at the end of Year 1, Year 2, Year
3 and Year 4 and PURCHASER will pay the resulting difference to SELLER. At the end of the then current Year, SELLER shall calculate the Minimum Yearly Quantities based on the quantities of the Device delivered to PURCHASER pursuant to Purchase
Orders placed for such year. At such time, if PURCHASER has not met the Minimum Yearly Quantities, then SELLER shall send an invoice setting forth (i) a calculation of the actual shipped quantities of the Device at the applicable Purchase Price
and (ii) the difference between such due amount and any amounts paid by 

  
 ***Confidential
Treatment Requested 
 20 

 
PURCHASER as of such date. PURCHASER shall pay such invoiced amount in full within [...***...] of the date of SELLER’s invoice. 

In the event that Purchaser fails to fulfill the Minimum Yearly Quantities for [...***...] and [...***...], SELLER retains the right to
reevaluate the Price Levels as set forth above in Schedule C.1, taking into account the Producer Price Index (“All Other Plastics Product Manufacturing”) from the US Bureau of Labor Statistics. 

The Parties agree to meet in good faith to discuss extension of supply no later than [...***...] prior to the end of the Year 4 as set forth in
this Agreement. SELLER agrees to extend the supply term in one-year increments, beginning Year 5, provided, SELLER and PURCHASER find an agreement on terms and conditions similar to the ones set forth in this Agreement. In particular prices need to
be agreed by SELLER prior to any extension of this Agreement. Year 5 is defined as the fifth year following FDA Approval of the Finished Product. 
 The Parties agree that prices may be adjusted annually based on the Producer Price Index (“All Other Plastics Product Manufacturing”) from the US Bureau of Labor Statistics. 

The lot size for the Device is no less than [...***...] units and no more than [...***...] units. 

The SELLER’s standard packaging and packing specifications are attached in Exhibit F. 

Currency Adjustments. 
 SELLER shall
calculate the impact of such evolution and inform PURCHASER accordingly. For purposes of clarity, this mechanism is designed for the parties to share the risk of currency fluctuations. 
 Currency adjustments only apply for products related to the Device made and imported from Europe (“Imported Products”). As of the Effective Date, two (2) components of the device are
imported from Europe. 
 [...***...] 
 [...***...] 
 On [...***...] of each year of this Agreement (the
“Currency Adjustment Date”), the Purchase Price of Imported Products only will be revised to reflect fluctuation of the currency exchange rate between the US Dollar and the Euro, compared to the initial base exchange rate on
December 31st, 2009, which shall be [€1
=US$1.40] (the “Base Rate”). On each Currency Adjustment Date, the average exchange rate of the Euro to the US Dollar shall be calculated since the Effective Date or for the prior twelve (12) months. If such floating average
differs from the Base Rate then in effect by at least [...***...] then, and only then, will the percentage change (positive or negative) to the exchange rate over such twelve (12) month period shall be computed and [...***...] of
such percentage change shall be multiplied by the then current US Price to determine the actual US Price that SELLER will invoice to PURCHASER 

  
 ***Confidential
Treatment Requested 
 21 

 for all Devices shipped to PURCHASER for after such Currency Adjustment Date. Examples of the
calculation of the currency adjustment described herein are set forth below. 
 Sample Calculation for Currency Pricing Adjustment

 1) If the Floating Average Rate as of [...***...] = [...***...], then NO CHANGE ([...***...] g 1.40 < [...***...]). 
 2) If the Floating Average Rate as of [...***...] =
[...***...], the Price will be adjusted as follows: 
 [...***...] 
 Device Equipment Contribution 
 The Device Equipment Contribution to be paid by PURCHASER to
SELLER is US-$ [...***...]. This contribution includes SELLER’s standard validation process. Any extra work, such as, but not limited to, analytical testing, performance studies or extractable studies, shall be subject to reasonable
commercial terms. 
 Invoice Milestones for Device Equipment Costs 
 First Payment: US-$[...***...] 
 Milestone: the Effective Date. 

Second Payment: US-$[...***...] 

Milestone: first available samples of all components out of moulds. 
 Third payment: US-$[...***...] 
 Milestone: qualified components within specification.

 Fourth payment: US-$[...***...] 
 Milestone: Operational Qualification, Installation Qualification, Performance Qualification of assembly equipment. 
 All prices for Device Equipment are calculated using an exchange rate of 1€ = 1.40 US-$. On any day that any milestone payment for the Device Equipment is invoiced by SELLER to PURCHASER, the US-$
amount shall be calculated utilizing an exchange rate equal to the final daily exchange rate as published in the Wall Street Journal, or if the Wall Street Journal ceases to publish an exchange rate, such comparable publication. 

  
 ***Confidential
Treatment Requested 
 22 

 EXHIBIT D: EXCLUSIVITY 

SELLER is willing to supply the Device to PURCHASER on an exclusive basis (“Exclusivity”) for the specific application defined below and
in accordance with the following terms: 
  

	 	1.	Application, Drug molecule 

For sublingual/buccal unit dose application of liquid formulations of Fentanyl. 

 

	 	2.	Exclusivity Payments 

Notwithstanding the provisions set forth in Exhibit C or further provisions set forth in this Exhibit D, to retain the
exclusive rights to the Device globally will be as follows. 
 Upon receipt of FDA Approval of the Finished Product, a Success
Fee of [...***...] will be paid by the PURCHASER to the SELLER. The Success Fee will be paid by the PURCHASER in [...***...], with [...***...]. This will grant PURCHASER Exclusivity from the date of NDA submission of the Finished
Product to end of the first year from the date following FDA Approval of the Finished Product, Year 1. 
 To maintain Exclusivity
in the United States for all subsequent years, an annual purchase and delivery requirement of the Device shall be a minimum of [...***...] (the “Exclusivity Quantity or Exclusive Quantities”). Commercially available IMS data
will be purchased by the PURCHASER and distributed to the SELLER on a [...***...] basis of the non-extended release Fentanyl products. This includes the currently existing non-extended release Fentanyl products and future launched non-extended
release Fentanyl products. To maintain Exclusivity in the rest of the world, PURCHASER, in addition to the purchase of the minimum Exclusive Quantities, must actively seek Marketing Approval (e.g. public press release, European clinical trials, or
public licensing announcements) for the Finished Product in one or more major markets in Europe (e.g. France, Germany and the United Kingdom) within [...***...] of the FDA Approval of the Finished Product. 

In the event that the PURCHASER has not purchased the Exclusivity Quantity, Purchaser will pay shortfall compensation to Seller in the
amount of [...***...] of Devices not procured, with payment in full due within fifteen (15) days of notification from SELLER (the “Shortfall Fee”). In the event that Purchaser fails to fulfill the Exclusivity Quantity
requirement for [...***...] consecutive [...***...], SELLER retains the right to terminate any and all Exclusivity terms previously granted to Purchaser and reevaluate the pricing set forth in Exhibit C of this Agreement.

  
 ***Confidential
Treatment Requested 
 23 

 The SHORTFALL FEE shall be calculated on [...***...] basis, starting with
[...***...] with the issue of the first purchase order by PURCHASER. If the number of Devices per [...***...] exceeds the Exclusivity Quantity for the previous [...***...], such exceeding quantities shall not be taken into
consideration for the following [...***...]. In no event shall SHORTFALL FEE be due or owing in the event of a failure or inability of Seller to supply the Device during such [...***...] period. 

Exclusivity expires immediately, should regulatory approval be revoked or should the Finished Product be withdrawn from the market in the
US. 
  

	 	3.	Territory 

 To the extent
permitted by applicable law and as otherwise provided herein, the territory 
 of Exclusivity granted by SELLER is valid
worldwide. 
  

	 	4.	Timeline 

 Based on
payment of the Success Fee and on the minimum quantities purchased set forth above, Seller is willing to grant Exclusivity to Purchaser commencing upon date of NDA submission of the Finished Product, unless by the date of signature of this contract
SELLER has entered into other obligations with third parties which may be adversely affected by granting such Exclusivity. Exclusivity terms as stated in this Exhibit D are granted until the end of [...***...] or [...***...], whichever
comes first (“Exclusivity Term”). The Parties agree to meet in good faith to discuss extension of Exclusivity no later than [...***...] prior to the end of the Exclusivity term as set forth in this Agreement. 

  
 ***Confidential
Treatment Requested 
 24 

 EXHIBIT E: STANDARD TERMS AND CONDITIONS 

 

  
 25 

 

 

  
 26 

 EXHIBIT F: STANDARD PACKAGING AND PACKING SPECIFICATIONS 

 

	1.	Packing 

	1.1.	Bag Preparation 

	 	1.1.1.	[...***...] 

  

	 	1.1.2.	[...***...] 

  

	 	1.1.3.	[...***...] 

  

	 	1.1.4.	[...***...] 

  

	1.2.	Carton Sealing 

  

	 	1.2.1.	[...***...] 

	1.3.	Carton filling/ Pharmaceutical Packaging Area 

  

	 	1.3.1.	[...***...] 

  

	 	1.3.2.	[...***...] 

  

	 	1.3.3.	[...***...] 

  

	 	1.3.4.	[...***...] 

  

	 	1.3.5.	[...***...] 

  

	1.4.	Labeling and closing of carton 

  

	 	1.4.1.	[...***...] 

  

	 	1.4.2.	[...***...] 

  

	 	1.4.3.	[...***...] 

  

	 	1.4.4.	[...***...] 

  

	1.5.	Packaging Records 

  

	 	1.5.1.	[...***...] 

  

	1.6.	Palletization 

  

	 	1.6.1.	[...***...] 

  

	 	1.6.2.	[...***...] 

  

	1.7.	Shipment preparation 

  

	 	1.7.1.	[...***...] 

  
 ***Confidential
Treatment Requested 
 27 

	 	1.7.2.	[...***...] 

  

	 	1.7.3.	[...***...] 

  

	 	1.7.4.	[...***...] 

  

	 	1.7.5.	[...***...] 

  

	 	1.7.6.	[...***...] 

  

	 	1.7.7.	[...***...] 

  

	1.8.	Stretch Wrap 

  

	 	1.8.1.	[...***...] 

  

	 	1.8.2.	[...***...] 

  

	 	1.8.3.	[...***...] 

  

	1.9.	Paperwork 

  

	 	1.9.1.	[...***...] 

  

	 	1.9.2.	[...***...] 

  

	 	1.9.3.	[...***...] 

  

	1.10.	Bill of Lading 

  

	 	1.10.1.	[...***...] 

  

	 	1.10.2.	[...***...] 

  

	1.11.	Pick up by carrier 

  

	 	1.11.1.	[...***...] 

  
 ***Confidential
Treatment Requested 
 28 

	 	1.11.2.	[...***...] 

  

	 	1.11.3.	[...***...] 

  

	1.12.	Communication of Shipment 

  

	 	1.12.1.	[...***...] 

  

	 	1.12.2.	[...***...] 

  

	 	1.12.3.	[...***...] 

  

	1.13.	Palletization of Finished Products: 

  

	 	1.13.1.	[...***...] 

  

	 	1.13.2.	[...***...] 

  

	 	1.13.3.	[...***...] 

  

	 	1.13.4.	[...***...] 

  

	 	1.13.5.	[...***...] 

  

	 	1.13.6.	[...***...] 

  

	 	1.13.7.	[...***...] 

  

	 	1.13.8.	[...***...] 

  

	 	1.13.9.	[...***...] 

  
 ***Confidential
Treatment Requested 
 29Eleventh Supplemental Indenture

 Exhibit 4.1 
 ELEVENTH SUPPLEMENTAL INDENTURE 
 ELEVENTH SUPPLEMENTAL INDENTURE (this
“Supplemental Indenture”), dated as of August 16, 2011, among PAETEC Holding Corp., a Delaware corporation (the “Company”), each of the entities listed on Annex A attached hereto as Subsidiary Guarantors (the
“Subsidiary Guarantors”), and The Bank of New York Mellon (formerly known as The Bank of New York), as trustee under the Indenture referred to below (the “Trustee”). 

RECITALS 

WHEREAS, the Company and certain of its Subsidiary Guarantors have heretofore executed and delivered to the Trustee an Indenture,
dated as of July 10, 2007 (as supplemented by the First Supplemental Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture, the Fourth Supplemental Indenture, the Fifth Supplemental Indenture, the Sixth Supplemental
Indenture, the Seventh Supplemental Indenture, the Eighth Supplemental Indenture, the Ninth Supplemental Indenture, and the Tenth Supplemental Indenture referred to below, the “Indenture”), providing for an initial issuance of an
aggregate principal amount of $300,000,000 of the Company’s 9.5% Senior Notes due 2015 (the “Notes”) and Subsidiary Guarantees of the Notes by the Subsidiary Guarantors, and the Company and other Subsidiary Guarantors have
heretofore executed and delivered to the Trustee a First Supplemental Indenture, dated as of September 25, 2007 (the “First Supplemental Indenture”), a Second Supplemental Indenture, dated as of February 8, 2008 (the
“Second Supplemental Indenture”), a Third Supplemental Indenture, dated as of December 18, 2009 (the “Third Supplemental Indenture”), a Fourth Supplemental Indenture, dated as of April 23, 2010 (the
“Fourth Supplemental Indenture”), a Fifth Supplemental Indenture, dated as of June 22, 2010 (the “Fifth Supplemental Indenture”), a Sixth Supplemental Indenture, dated as of October 15, 2010 (the
“Sixth Supplemental Indenture”), a Seventh Supplemental Indenture, dated as of December 6, 2010 (the “Seventh Supplemental Indenture”), an Eighth Supplemental Indenture, dated as of December 6, 2010 (the
“Eighth Supplemental Indenture”), a Ninth Supplemental Indenture, dated as of May 5, 2011 (the “Ninth Supplemental Indenture”), and a Tenth Supplemental Indenture, dated as of June 3, 2011 (the
“Tenth Supplemental Indenture); 
 WHEREAS, Section 9.02 of the Indenture provides, among other things,
that the Company and the Subsidiary Guarantors, when authorized by their Board of Directors (as evidenced by a Board Resolution), and the Trustee may amend the Indenture and the Notes with the written consent of the Holders of a majority in
aggregate principal amount of the Notes then outstanding (the “Requisite Consents”) as calculated in accordance with Section 2.10 of the Indenture; 
 WHEREAS, the Company has obtained the Requisite Consents from the Holders to amend certain provisions of the Indenture on the terms hereinafter provided; and 

WHEREAS, all acts and requirements necessary to make this Supplemental Indenture the legal, valid and binding obligation of the
Company and the Subsidiary Guarantors have been done; 

 NOW THEREFORE, in consideration of the foregoing and for other good and valuable
consideration, the receipt of which is hereby acknowledged, the parties mutually covenant and agree as follows: 
 ARTICLE ONE

 Definitions 
 1. Capitalized Terms. Capitalized terms used in this Supplemental Indenture (including the recitals hereto) without definition shall have the meanings set forth in the Indenture. 

ARTICLE TWO 

Amendments 

Subject to the execution and delivery hereof by the parties hereto, the Indenture is hereby amended as follows: 

1. Amendment to Section 1.01. Section 1.01 of the Indenture is hereby amended to add to Section 1.01 the following
term and definition, in the appropriate alphabetical order: 
 “PAETEC Merger” means the
acquisition of the Company by Windstream Corporation through the merger of Peach Merger Sub, Inc. with and into the Company, with the Company surviving as a wholly-owned subsidiary of Windstream Corporation, pursuant to the Agreement and Plan of
Merger, dated as of July 31, 2011, as the same may be amended, by and among Windstream Corporation, Peach Merger Sub, Inc. and the Company, together with the other transactions contemplated thereby.” 

2. Amendment to Section 4.11. Section 4.11 of the Indenture is hereby amended to add to the end of Section 4.11, as
a new final sentence thereto, the following sentence: 
 “Notwithstanding the foregoing and any other provision of the
Indenture or the Notes, this Section 4.11 shall not apply to a Change of Control resulting from the PAETEC Merger.” 

3. Amendment to Section 4.17. Section 4.17 of the Indenture is hereby amended to add to the end of Section 4.17 the
following new paragraph (f): 
 “(f) Notwithstanding the foregoing and any other provision of this Indenture
or the Notes, in the event that any direct or indirect parent company of the Company becomes a guarantor of the Company’s obligations under the Notes, the Indenture shall permit the Company to satisfy its obligations in this
Section 4.17 with respect to financial information and reports relating to the Company by furnishing the financial information specified in Section 4.17(a)(1) and the reports specified in Section 4.17(a)(2), in
each case, relating to such parent company; provided that the financial information specified in Section 4.17(a)(1) is accompanied by consolidating information that explains in reasonable detail the differences between the
information relating to such parent company, on the one hand, and the information relating to the Company and its Restricted Subsidiaries on a standalone basis, on the other hand.” 

  
 - 2 -

 4. Form of Note. The first paragraph set forth under Section 6 of Exhibit A
attached to the Indenture is hereby amended to add to the end of such paragraph, as a new final sentence thereto, the following sentence: 
 “Notwithstanding the foregoing and any other provision of the Indenture or the Notes, this Section 6 shall not apply to a Change of Control resulting from the PAETEC Merger.” 

5. Terms of Notes. The terms of the $300,000,000 of Notes authorized pursuant to and issued under the Indenture include the terms
in this Supplemental Indenture and the Indenture as amended thereby. The Notes are subject to all such terms and the Holders are referred to the Indenture for a statement of all such terms. To the extent permitted by applicable law, in the event of
any inconsistency between the terms of the Notes and the terms of the Indenture, the terms of the Indenture as amended hereby shall control. 
 ARTICLE THREE 
 Effectiveness 

This Supplemental Indenture shall become effective when executed by the parties hereto. 

ARTICLE FOUR 
 Miscellaneous 
 1. Ratification of Indenture; Supplemental Indenture
Part of Indenture. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a
part of the Indenture for all purposes, and every Holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby. 
 2. Trustee’s Disclaimer. The Trustee makes no representation or warranty as to the validity or sufficiency of this Supplemental Indenture. The recitals and the statements herein are deemed to
be those of the Company and the Subsidiary Guarantors and not of the Trustee. 
 3. Governing Law. THIS SUPPLEMENTAL
INDENTURE SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK. THE COMPANY, THE SUBSIDIARY GUARANTORS AND THE TRUSTEE AGREE TO SUBMIT TO THE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK IN ANY ACTION OR PROCEEDING ARISING OUT OF OR
RELATING TO THIS SUPPLEMENTAL INDENTURE. 
 4. Successors. All agreements of the Company and the Subsidiary
Guarantors in this Supplemental Indenture shall bind any successors thereto. 

  
 - 3 -

 5. Counterparts. This Supplemental Indenture may be executed in two or more
counterparts, all of which shall be considered one and the same agreement. 
 6. Effect of Headings. The Section headings
herein are for convenience only and shall not affect the construction thereof. 
 7. Conflict with the Trust Indenture
Act. If any provision of this Supplemental Indenture limits, qualifies or conflicts with any provision of the TIA that is required under the TIA to be part of and govern any provision of this Supplemental Indenture, the provision of the TIA
shall control. If any provision of this Supplemental Indenture modifies or excludes any provision of the TIA that may be so modified or excluded, the provision of the TIA shall be deemed to apply to the Indenture as so modified or to be excluded by
this Supplemental Indenture. 

  
 - 4 -

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed as of the date first written above. 
  

			
	
	The Company
	
	PAETEC Holding Corp.
		
	By:	 	 /s/ Mary K. O’Connell

	Name:	 	Mary K. O’Connell
	Title:	 	Executive Vice President, General Counsel and Secretary
	
	The Subsidiary Guarantors
	
	Each of the entities listed on Annex A attached hereto
		
	By:	 	 /s/ Mary K. O’Connell

	Name:	 	Mary K. O’Connell
	Title:	 	Senior Vice President, General Counsel and Secretary

 
			
	The Trustee
	
	The Bank of New York Mellon
		
	By:	 	 /s/ James M. Young

	Name:	 	James M. Young
	Title:	 	Senior Associate

 ANNEX A 

Access One Communications Corp. 
 Allworx Corp. 
 Cavalier IP TV, LLC 

Cavalier Services, LLC 
 Cavalier Telephone Corporation 
 Cavalier Telephone Mid-Atlantic, L.L.C.

 Cavalier Telephone, L.L.C. 
 CavTel Holdings, LLC 
 Compco, Inc. 

Elantic Networks, Inc. 
 Intellifiber Networks, Inc. 
 LDMI Telecommunications, Inc. 

McLeodUSA Information Services LLC 
 McLeodUSA LLC 
 McLeodUSA Purchasing, L.L.C. 

McLeodUSA Telecommunications Services, L.L.C. 
 MPX, Inc. 
 Network Telephone Corporation 

NT Corporation 

OmniCall, Inc. 

PaeTec Communications of Virginia, Inc. 
 PaeTec Communications, Inc. 
 PAETEC Corp. 

PAETEC Integrated Solutions Group, Inc. 
 PAETEC iTel, L.L.C. 
 PAETEC Realty LLC 

PaeTec Software Corp. 
 Pyramid Communication Services, Inc. 
 Quagga Corporation 

SM Holdings, LLC 

Talk America Holdings, Inc. 
 Talk America Inc. 
 Talk America of Virginia, Inc. 

TC Services Holding Co., Inc. 
 Technology Resource Solutions, Inc. 
 The Other Phone Company, Inc. 

U.S. Energy Partners LLC 
 US LEC Communications LLC 
 US LEC LLC 

US LEC of Alabama LLC 
 US LEC of Florida LLC 
 US LEC of Georgia LLC 

US LEC of Maryland LLC 
 US LEC of North Carolina LLC 
 US LEC of Pennsylvania LLC 

US LEC of South Carolina LLC 
 US LEC of Tennessee LLC 
 US LEC of Virginia L.L.C. 

XETA Technologies, Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}]]